Methods
Informed consent to monitor, treat and report the subject was obtained from the patient and approved by the West Palm Beach VAMC Research & Development Committee. Nasopharyngeal swab specimens were obtained from the patient. Samples were shipped to Orlando for performance of the Gene Xpert Cepheid Innovation XPRSARS-COv2-10 RT PCR assay measuring viral N2 sequence abundance. The limit of detection was 0.01 plaque forming units/mL (CFU/mL) or 250 viral RNA copies/mL with first cycle number above background (Cq) of 39. Blood samples were collected using a serum separator tube and serum also shipped to Orlando for performance of the Abbott Architect anti-N SARS CoV-2 IgG assay with resultsĀ calculated as chemiluminescence ratios of sample to control with negative ratios being <1.4.